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Abstract  
This study was aimed to investigate gene polymorphism of macrophage migration inhibitory factor (MIF) at -
173 locus as risk factor of bladder cancer in Iraqi population by PCR-RFLP. Accordingly 135 Iraqi Arab 
subjects were distributed as 73 patients with urinary bladder carcinoma (UBC), 32 patients with urinary bladder 
disorders and 30 healthy controls. The frequency distributions of genotypes and alleles of the groups showed the 
GG and G allele were (61.9 and 78.77) % among the UBC cases with positive association with no significant 
relative risk (RR) value1. 41 and etiological factor (EF) value of 0.1 8 and (56.3 and 75)% among the UBD cases 
while represent (53.3and 70)% respectively among healthy cases and no significant variation was recorded 
between UBC and control. 
 Keywords: MIF Polymorphism; Bladder cancer. 
1. Introduction  
Bladder cancer is abnormal cells multiply without control in the bladder  arising from the epithelial lining 
(the urothelium) of the urinary bladder  has the highest recurrence rate of any malignancy.  
------------------------------------------------------------------------ 
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Rarely the bladder is involved by non-epithelial cancers, such as lymphoma or sarcoma. Bladder cancer 
generates the highest medical cost per patient and it is the fifth most expensive cancer in terms of total medical 
care expenditures. Approximately 95% of malignant bladder tumors are urothelial cell carcinomas (UCC) which 
can be classified as papillary (most common type, tend to grow slowly towards the lumen), solid (less frequent, 
infiltrate the bladder wall and are more aggressive) or carcinoma In Situ (CIS, a very aggressive kind of cancer 
that involves only the inner lining of the bladder [1,2,3,4]. 
Macrophage migration inhibitory factor (MIF) is pro-inflammatory cytokine shown to promote tumorigenesis 
discovered in 1966.  The MIF gene coded 12.5 kDa polypeptide and the protein consists of 115 amino acids 
which lies on chromosome 22q11.2 and regulation of the gene is by the two polymorphic sites in the promoter 
region .The first site consists of the CATT repeat at -794 which repeats 5-8 times and the second site is a single 
nucleotide polymorphism at -173(G/C). This site is associated with enhanced promoter activity in some cancer 
cell lines and the activity is proportional increased MIF levels in serum [5,6,7,8].MIF enhancement of 
macrophage transcription, activation and viability, coupled with its inhibitory effects on anti-tumor cell 
cytotoxic lymphocytes, suggests that MIF overexpression in developing malignancies may act in concert to 
facilitate increased tumor growth which  present an important link between inflammation and cancer due to its 
pro-inflammatory role. Its molecular mechanisms involve, among others, the inhibition of p53 which promote 
tumor cell proliferation, cell survival and tumor-associated neoangiogenesis [9,10].  MIF binds to extracellular 
domain of CD74with high affinity and initiates a signaling cascade. CD74 forms a complex with CD44which is 
essential for the MIF-induced signaling cascade. Rare (SNPs) in the CD74 gene have been reported, but SNPs in 
molecules that interact with CD74, such as MIF, CD44and MHC class are more frequent and are associated with 
the development of cancer. The imbalance in the regulation of inflammation that occurs in many cancers can 
induce cellular damage. This stimulates interaction between immune cells and the damaged cells, which then 
proliferate, invade, and subsequently develop into tumors [11,12]. 
A DNA polymorphism is a difference in the nucleotide sequence between individuals of the same species. These 
differences can be single base pair changes, deletions, insertions, or even changes in the number of copies of a 
given DNA sequence. SNPs (single nucleotide polymorphisms) are the most common type of DNA 
polymorphism in humans. An example of an SNP would be if a cytosine (C) nucleotide is present at a particular 
locus in one person’s DNA but a thymine (T) nucleotide occurs at the same locus in another person’s DNA. A 
polymorphic variant of a gene may lead to the abnormal expression or to the production of an abnormal form of 
the gene; this may cause or be associated with disease [13,14].   
Cancer results from a series of genetic alterations leading to a progressive disorder of the normal mechanisms 
controlling growth, differentiation, cell death, or genomic instability. The response of the cell to genetic injury 
and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are essential in 
preventing tumor initiation and progression. Polymorphisms of several DNA repair-related genes and some 
cytokine genes have been found to be associated with the risk of developing different tumor types.  Polymorphic 
alleles of DNA genes would predispose carriers to a higher risk of developing cancer but would not necessarily 
cause cancer. Therefore, possible gene–gene interaction and gene–risk factor interaction may play an important 
role in modifying the cancer risk associated with particular gene polymorphism in different study populations 
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[15,16,17]. The nucleotide sequences of DNAs in humans are not identical in different individuals. Nucleotide 
substitutions have been estimated to occur every few hundred base pairs in the human genome. Nucleotide 
sequence polymorphism has been detected as restriction fragment length polymorphism (RFLP). Although 
RFLPs are very useful for distinguishing two alleles at chromosomal loci, they can be detected only when DNA 
polymorphisms are present in the recognition sequences for the corresponding restriction endonucleases or when 
deletion or insertion of a short sequence is present in the region detected by a particular probe. In recent years, 
several functional polymorphisms, particularly, SNPs have been identified in cytokines and their receptor genes 
that regulate levels of cytokine expression. These have been implicated as immune prognostic markers in 
diseases, including differential response to therapy and as biomarkers of graft outcome following organ and 
stem cell transplantation. Population distribution of cytokine gene polymorphisms (CGPs) reveals significant 
variations in allele frequencies in different ethnic groups and this might explain, to some extent, the observed 
differences in SNP associations with various diseases and immune-pathologies [18,19,20,21] 
2. Materials and Methods 
2.1 Patients   
A total of 73 subjects diagnosed with bladder cancer, 32 subjects had urinary bladder disorder and 30healthy 
controls were consecutively recruited from The AlYarmook Teaching Hospital and AlJabchi privet Hospital 
between  March 2014 and November  2014. All cases were urology clinic patients with histological confirmed 
transitional cell carcinoma, were consent to participate in the study, and donated 5 mL of blood. The controls 
were genetically unrelated cancer-free individuals living in the same residential areas and frequency-matched to 
the cases on age, sex, smoking status, and alcohol use.  
2.2 Genotyping   
Genomic DNA was extracted from peripheral blood by Using relia –prep kit (Promega/USA) .The DNA pellet 
was resuspended in TE (Tris-EDTA) buffer (Promega /USA) then  purity and concentration were determined by 
spectrophotometric measurement of absorbance at 260 and 280 nm. The MIF-173G/C polymorphism was 
determined by using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) 
method. The primers designed in this study were as follows: /5ACTAAGAAAGACCCGAGGC/3 (forward) 
and/5 GGGGCACGTTGGTGTTTA/3 (reverse). Amplification was carried out in 0.2 mL thin-wall PCR strip 
tubes (Eppendorff/Germany ) containing 12.5µl of master mix , 8.5 µl ddH2O, 2 µl template DNA and  1 µl of  
each forward and reverse primers(Alpha DNA, Canada).The cycling conditions comprised a hot start at 95°C 
for5 min, followed by 35 amplification cycles at 95°C for 1min , 60°C for 1 min, and 72°C for 1mins, and a 
final extension at 72°C for 5 min. The PCR product was a 366 bp fragment that contained both the polymorphic 
and a non-polymorphic AluI site. Amplified PCR product (20µL) was digested in a 25 µl final reaction volume 
using 5µl of  reaction buffer and 10 units of AluI restriction enzyme  at 37°C for 3 hours. The gel was then 
stained with ethidium bromide. The digestion fragments for the polymorphisms were separated by 3% agarose 
gel. Since G/G gene type cannot be cut off by AluI restriction enzyme at -173, we got two fragments as 268- and 
98-bp; C/C gene type can be digested by AluI at -173, so we got 62-, 206- and 98-bp three fragments; and it 
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turns out to be four fragments as 62-, 98-, 206- and 268-bp after digestion of G/C type by AluI. 
2.3 Determination of Serum MIF  
Serum level of MIF measured by using ELISA kit (R&D, USA), based upon coating wells of a high protein 
binding ELISA plate with monoclonal antibody specific for human MIF. Standard and sample were added to 
appropriate well followed by covering the plate with the adhesive strip and incubates for 2 hours at room 
temperature then washed four times with wash buffer. 200μl of cytokine conjugate was added to each well and 
covered with a new adhesive strip, incubated for 2 hours at room  temperature on the shaker then  washed four 
times . 200 μl of substrate solution was added to each well and incubated for 30 min at room temperature in 
dark. Finally,50 μl of stop solution was added to each well. The color in the wells should change from blue to 
yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to 
ensure thorough mixing. The optical density of each well was measured within 30 minutes, using a microplate  
reader set to 450 nm. 
3. Results and Discussion  
MIF Gene Polymorphism at -173  
Macrophage migration inhibitory factor (MIF ) is an inflammatory factors may promote carcinogenesis which 
derived from T-cell, known as a member of the transforming growth factor-β (TGF-β) superfamily, plays an 
important role in the pro- and anti-inflammatory response to infection and in the etiology of bladder 
cancer[22].MIF-173 locus polymorphism  might contribute to genetic susceptibility to bladder cancer. In a 
hospital-based case–control study of 73 patients with bladder cancer and 62 cancer-free controls  then genotyped 
the MIF polymorphism. Genomic DNA were  extracted from peripheral blood of all 135 subjects then amplified 
DNA by PCR with using specific primer for -173 locus  that gave  the PCR product (366) bp  as shown as in 
Figure (1).The frequency distributions of genotypes and alleles  of the groups  are presented in Table(1) . The 
GG, GC, and CC genotype frequencies were 61.9%, 31.6% and 5.5%, respectively among the  UBC cases and 
56.3, 37.5, and 6.2%, respectively, among the UBD cases while represent 53.3 %,33.3% and 13.4% respectively 
among healthy cases.  
As a protective factor, the CC genotype frequency of MIF was lower among the cases. Results  nearly agreed 
with results reported by Yuan and his colleagues,(2012)  who found that individuals with GC/CC genotype had 
a significantly decreased risk of bladder cancer than those with GG genotype. MIF polymorphism, the GG, GC, 
and CC genotype frequencies were 63.4, 30.5, and 6.1%, respectively, among the cases and 50.7, 43.2, and 
6.1%, respectively, among the controls., thus MIF -173G/C polymorphism may play a role in the etiology of 
bladder cancer in southern Chinese population .Macrophage migration inhibitory factor (MIF) is a pro-
inflammatory cytokine that plays a significant role in pathogenesis and autoimmune diseases and  functional 
polymorphisms in human MIF that separate the population into those with high and those with low expression 
of MIF. 
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Figure1: Gel electrophoresis for amplification of  human MIF gene. 
Electrophoresis was performed on 1.2 % agarose gel and run with a 70 volt current for 2 hrs. Lane M is a 
(100bp) ladder 
 
Figure 2: Gel Electrophoresis of MIF -173 polymorphism (RFLP by Alu1);M: DNA Marker; G/G:   
Homozygous for absence of Alu1 restriction site (268bp,98bp); C/C: Homozygous for Alu1 restriction site 
(206bp,98bp,62bp);G/C:Heterozygous for Alu1 restriction site (268bp,206bp,98bp,62bp). 
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Table 1: Genotypes distribution among UBC, UBD and healthy 
 
Genotype 
Groups Total 
UBC UBD Healthy No. % 
No. % No. % No. % 
GG 45 61.6 18 56.3 16 53.3 79 58.5 
GC 24 32.9 12 37.5 10 33.3 46 34.1 
CC 4 5.5 2 6.2 4 13.4 10 7.4 
Total 73 54.1 32 23.7 30 22.2 135 100 
The human MIF gene locates on chromosome 22q11.2 and contains 3 exons and 2 introns .Gene  mapping has 
shown that the MIF gene displays polymorphism, including microsatellite polymorphism and single nucleotide 
polymorphism, at 4 sites. G/C polymorphism locates at -173, T/G polymorphism locates at +254, C/G 
polymorphism locates at +656, and a CATT repetitive sequence locates at -794. −173G/C polymorphism may 
be associated with cancer risk[23,24,25].The  genotypes and allele frequencies of MIF polymorphism and its 
association with risk  of bladder cancer are summarized in table (2).            
Table 2: Observed numbers  alleles frequencies(Hardy-Weinberg equilibrium ) of the MIF at -173 SNP in 
UBC,UBD and Control 
Group 
MIF-173 Genotype or Allele 
H-W (P≤) 
GG GC CC G C 
 
UBC 
 
Observed 
No. 46 23 4 115 31 
 
N.S 
% 61.9 31.6 5.5 78.77 21.23 
Expected 
No. 45.29 24.42 3.29 
Not Estimated 
% 62 33.45 4.5 
 
UBD 
Observed 
No. 18 12 2 48 16 
 
N.S 
% 56.25 37.50 6.25 75 25 
Expected 
No. 18 12 2 
Not Estimated 
% 56.25 37.50 37.50 
Control 
Observed 
No. 16 10 4 42 18 
N.S 
% 53.33 33.33 13.34 70 30 
Expected 
No. 14.7 12.6 2.7 
Not Estimated 
% 49 42 9 
 
N.S : Not Significant  
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Nishihira and his colleagues, (2003) reported that  MIF has the potential to promote tumor growth and tumor-
associated angiogenesis in mice and mice bladder cancer experiment, while Arikan and his colleagues,(2006) 
revealed that MIF-173C allele frequency was significantly higher in biliary atresia patients than both the chronic 
liver disease patients and healthy control groups and  Makhija and his colleagues ,(2007) reported that the MIF-
173C alleles was over expressed in acute pancreatitis patients. Their data all suggested that the polymorphisms 
might affect on MIF protein expression and activity thus the variation in MIF may play a role in etiology of 
bladder cancer. Although, how the MIF-173 G/C polymorphisms affect the inflammatory factor activity remains 
to be investigated, some studies suggested that the polymorphisms may affect the protein functions. The 
frequency of  GG genotype was increased as well as G allele  which had positive association with RR value1.32  
and EF value 0.13 while GC and CC genotypes were decreased as well as C allele , both of them had negative 
association with RR value 0.78,0.69 respectively .such  two negative association scored PF value as shown in 
table(3). 
Table 3: Statistical evolution of association between MIF -173 genotypes or alleles and urinary bladder 
carcinoma 
MIF-173 Genotype 
or   Allele 
Statistical Evolution 
Relative 
Risk 
Etiological 
Or 
Preventive Fraction 
Fisher's Exact 
Probability 
95% Confidence Intervals 
G/G 1.41 0.18 0.510 0.60-3.28 
G/C 0.98 0.07 0.569 0.40-2.42 
C/C 0.38 0.08 0.170 0.09-1.59 
G 1.59 0.29 0.123 0.81-3.12 
C 0.63 0.11 0.123 0.32-1.24 
 
Single nucleotide polymorphisms (SNP) in inflammation genes have been shown to alter their expression and 
functions. A G/C SNP in the promoter region (174) of IL-6 was shown to affect transcription and alter plasma 
IL-6 levels. The A-allele of an IL-8 SNP in the promoter region (T-251A) has been associated with increased 
IL-8 production by lipopolysaccharide-stimulated whole blood. A G-to-A transition in the promoter region 
(308) of the TNF- gene results in higher expression of TNF. 
Results showed that MIF level in GG was (62.69) pg/ml significantly higher in UBC. A significant decrease was 
recorded in UBD and healthy (37.98 and 16. 61 pg/ml) respectively. In GC genotype MIF level was (52.51) 
pg/ml followed by (38.16) pg/ml in UBD and (22.38) pg/ml in healthy with significant differences. A significant 
increase was recorded in CC genotype in UBC and UBD (53.54 and 54.60) pg/ml respectively in comparison in 
healthy (16. 57) pg/ml with significant differences (p≤ 0.01). 
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Table (4): Association between different genotypes and MIF level in UBC , UBD and healthy. 
Genotype 
Group (Mean level of MIF Mean± SE) pg/ml 
Significant between groups 
P-value 
 UBC UBD Healthy 
GG 62.69 ± 5.52 37.98 ± 2.46 16.61 ± 0.79 13.685 ** 0.0027 
GC 52.51 ± 3.57 38.16 ± 4.51 22.38 ± 3.21 18.702 ** 0.0001 
CC 53.54 ± 6.54 54.60 ± 16.50 16.57 ± 1.78 18.963 ** 0.0001 
LSD -value 15.355 NS 19.050 NS 11.163 NS ---- 
Different letters means significant differences between mean P≤ 0.01  
Meyer-Siegler et al .,(2007) reported the concentration of MIF is higher in bladder cancer tissue than in normal 
bladder tissue especially in muscle invasive bladder cancer tissue  and in  functional promoter, the MIF-173 
situate in the 50 flanking region of MIF gene, which is strongly associated with protein production. Also, MIF 
allele defined by -173C SNP was associated independently with prostate cancer and independently with elevate 
levels of circulating MIF. The human MIF gene had a single nucleotide polymorphism (SNP; G to C  transition) 
in the 50-flanking region at position -173,which has been associated with susceptibility to adult inflammation 
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